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ABSTRACT
Polycomb proteins play key roles in mediating epi-
genetic modifications that occur during cell differ-
entiation. The Polycomb repressive complex 2
(PRC2) mediates the tri-methylation of histone H3
lysine 27 (H3K27me3). In this study, we identify a
distinguishing feature of two classes of PRC2
target genes, represented by the Nr2F1 (Coup-TF1)
and the Hoxa5 gene, respectively. Both genes are
transcriptionally activated by all-trans retinoic acid
(RA) and display increased levels of the permissive
H3K9/K14ac and tri-methylated histone H3 lysine 4
epigenetic marks in response to RA. However, while
in response to RA the PRC2 and H3K27me3 marks
are greatly decreased at the Hoxa5 promoter, these
marks are initially increased at the Nr2F1 promoter.
Functional depletion of the essential PRC2 protein
Suz12 by short hairpin RNA (shRNA) technology
enhanced the RA-associated transcription of
Nr2F1, Nr2F2, Meis1, Sox9 and BMP2, but had no
effect on the Hoxa5, Hoxa1, Cyp26a1, Cyp26b1 and
RARb2 transcript levels in wild-type embryonic stem
cells. We propose that PRC2 recruitment attenuates
the RA-associated transcriptional activation of a
subset of genes. Such a mechanism would permit
the fine-tuning of transcriptional networks during
differentiation.
INTRODUCTION
The ability to self-renew and differentiate into speciﬁc cell
lineages in response to external stimuli is a unique property
of pluripotent stem cells. This ability makes embryonic
stem (ES) cells an excellent model for in vivo differentiation
(1). All-trans retinoic acid (RA), a metabolite of vitamin A,
induces epigenetic and transcriptional changes under-
pinning the differentiation of various stem cells, including
ES cells (2,3). Several key regulators of stem cell differen-
tiation exhibit a bivalent chromatin structure possessing
both repressive and permissive histone modiﬁcation, tri-
methylated histone H3 lysine 27 (H3K27me3) and tri-
methylated histone H3 lysine 4 (H3K4me3), respectively
(4). Differentiation of stem cells, e.g. during neurogenesis,
involves epigenetic changes, which resolves bivalent regions
into either active H3K4me3-rich, or repressive H3K27me3-
rich, domains (5,6).
The Polycomb Repressive Complex 2 (PRC2) is a multi-
protein complex that confers transcriptional repression via
the placement of the repressive H3K27me3 histone mark.
Indeed, Polycomb repressive complexes (PRC1/2) silence
many genes in ES cells (7,8). The PRC2 protein Ezh2 is a
H3K27-speciﬁc histone methyltransferase that, via epigen-
etic modiﬁcation of histones, controls aspects of cell fate
choice during differentiation (9). Ezh2 deposits the
H3K27me3 repressive mark recognized by PRC1 factors,
which leads to Ring1 mono-ubiquitination of histone H2A
lysine 119 (8,10,11). Ezh2, Suz12 and Eed proteins form
the core of the PRC2 complex, and the methyltransferase
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activity of PRC2 requires both Ezh2 and Suz12 (12,13).
While the role of epigenetic modiﬁcations at promoter
proximal regions has been extensively studied (4), the
mechanisms by which epigenetic changes at distal
enhancer sites inﬂuence transcription and how these
relate to the PRC function at proximal promoters are
only now emerging (14,15).
Vitamin A (retinol) and its natural and synthetic
analogs, retinoids, exert profound effects on many biolo-
gical processes [for review see (2,3)]. The retinol metabol-
ite all-trans RA mediates most biological effects of retinol
(16), and has been implicated in numerous in vivo differ-
entiation pathways (17). The actions of RA are primarily
mediated by two classes of nuclear retinoid receptors:
retinoic acid receptors (RARs) and retinoid X receptors
(RXRs) (18). These nuclear receptors are members of the
steroid hormone or nuclear receptor superfamily that also
includes estrogen, androgen, thyroid hormone, peroxi-
some proliferator activated receptors and vitamin D
receptors. These receptors act as ligand-modulated tran-
scription factors that activate transcription of speciﬁc
target genes (19,20). We have previously shown that RA
treatment of ES and F9 cells leads to the removal of the
PRC2 complex from several RA target genes, including
Hoxa1, Cyp26a1 and RAR2 (21–24), and that the
removal of PRC2 is a key step in the transcriptional in-
duction of these direct/primary RA target genes (21,25). It
is unclear whether PRC2 displacement is a common
feature associated with RA-induced transcription.
Nr2F1 and Nr2F2 are also referred to as the chicken-
ovalbumin upstream promoter-transcription factors
(Coup-TF1/2). Nr2F1 and Nr2F2 belong to a diverse
group of nuclear receptors, which are termed orphan
nuclear receptors because physiological ligands have not
yet been identiﬁed (26). In mammals, only two genes,
Nr2F1 (Coup-TF1, EAR-3) and Nr2F2 (Coup-TF2,
ARP-1), have been identiﬁed, but homologs have been
cloned from numerous species (27,28). The high degree
of evolutionary conservation of the Coup-TF proteins
strongly suggests that they are primordial members of
the nuclear receptor family and that they have important
biological functions (29–32). We and others have shown
that RA-induced endodermal differentiation is associated
with increased Nr2F1 mRNA levels (33–35). We have
further demonstrated that ectopic expression of Nr2F1
enhances the RA-induced differentiation of ES cells into
extra-embryonic endoderm (35), which may suggest that
induction of Nr2F1 is a key event in the generation of
endodermal tissue. Consistent with this expression of
Laminin, which is required to separate the primitive
endoderm from the epiblast, is regulated by Nr2F1 (36).
Although Nr2F2 has been shown to bind RA (37), it is not
clear if Nr2F2 is activated by RA under physiological con-
ditions. The expression patterns of Nr2F1 and Nr2F2 are
partially overlapping in the early mouse embryo (E7.5),
but later in development, Nr2F1 is expressed mainly in the
nervous system, whereas Nr2F2 is predominantly ex-
pressed in the mesenchyme of internal organs such as
the pancreas (28). The roles of Nr2F1 and Nr2F2 in
RA-induced endodermal differentiation and the potential
association with RA suggest that these transcription
factors are key players in mediating the cellular response
to RA (38), yet how the expression of the Nr2F1 and
Nr2F2 is regulated by RA remains largely unknown.
In this study, we ﬁrst evaluate the effects of RA on the
epigenetic states of Nr2F1, Nr2F2, Hoxa5 and Hoxa1 in
F9 embryonal carcinoma stem cells. We demonstrate dif-
ferential Suz12 dynamics between two types of PRC2
target genes, represented by the Nr2F1 (Coup-TF1) and
Hoxa5 genes. We further evaluate both transcriptionally
permissive and PRC2-associated repressive epigenetic
marks. We extend these ﬁndings to ES cells, and delineate
the functional role of Suz12 in the RA-induced transcrip-
tion of the genes Nr2F1, Nr2F2, Meis1, Sox9, BMP2,
Hoxa5, Hoxa1, Cyp26a1, Cyp26b1 and RAR2. Our
ﬁndings identify PRC2 dynamics as a distinguishing
feature between two classes of RA-inducible stem cell
genes, both of which include several key regulators of dif-
ferentiation. We suggest that in addition to maintaining
transcriptional repression, the PRC2 complex attenuates
the transcriptional activation of speciﬁc genes during stem
cell differentiation.
MATERIALS AND METHODS
Cell culture and RNA extraction
F9 wild-type (WT), RAR/, RAR2
/ and RAR/
embryonal teratocarcinoma stem cells were cultured as
described (39–41). The RAR knockout cell lines were
validated by reverse transcriptase-polymerase chain
reaction (RT-PCR) (Supplementary Figure S1). WT (J1)
and knockdown ES lines were cultured as described (23).
Total cellular RNA was extracted using Trizol
(Invitrogen, CA) according to the manufacturer’s
protocol.
Generation of Suz12 knockdown cell lines
Generation of viral particles and transduction of ES cells
was previously described (42,43). In brief, knockdown
vectors pLKO shSuz12 (Cat. # TRCN0000038728,
Sigma Aldrich, MO) or pLKO shLuc (control), together
with packaging vectors pCMV8.9 and pVSV-G
(Cat. #631530, Clontech, CA), were transfected into
HEK293T cells using Lipofectamine 2000 (Cat. #
11668019, Invitrogen, CA). On overnight recovery, the
cells were replenished with fresh media and allowed to
produce virus for an additional 48 h before the super-
natant was harvested, ﬁltered through 0.45mm ﬁlters and
supplemented with polybrene. F9 and ES cells were
transduced with viral supernatant in a 1:1 ratio with 2
growth medium. About 16 h later, the cells were replen-
ished with media supplemented with puromycin
(0.5 mg/ml) for 10 days of propagation in the selection
media. In agreement with a previous publication (44),
the knockdown was validated by western blotting.
Semi-quantitative and Quantitative RT-PCR
Total RNA (3 mg) was used to synthesize cDNA with
random primers. The cDNA synthesis was performed at
42C for 1 h in a ﬁnal volume of 20 ml using qScript
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(Quanta, MD). PCR were performed using 2.5 102U
Taq DNA polymerase (Invitrogen, CA). Each cycle
included 94C for 30 s (denaturation), 58–64C for 45 s
(annealing) and 72C for 1min (extension). The number
of cycles required for PCR ampliﬁcation in the linear
range was determined experimentally for each gene. For
semiquantitative PCR, ampliﬁed PCR products were
resolved on 2% agarose gels and visualized by staining
with ethidium bromide. Primer pairs were either
obtained from published articles or designed using the
PrimerSelect program (DNAstar). The primer pairs were
evaluated using in silico PCR analysis (http://genome.
ucsc.edu/) to avoid pseudogenes. All primers were
designed to anneal to different exons to avoid any contri-
bution of genomic DNA to the signal. Sequences of gene-
speciﬁc primers are speciﬁed in the Supplementary
Table S1. All gene expression amplicons were validated
by sequencing.
Data processing and Statistical analysis of
quantitative PCR
The transcript levels in the biological triplicates (n=3)
were normalized to 36B4 transcript levels and statistical
signiﬁcance was determined by t-test (P< 0.05). The chro-
matin immunoprecipitation (ChIP) signals in the biolo-
gical triplicates (n=3) were normalized to percent input
and statistical signiﬁcance was determined by t-test
(P< 0.05). The standard error of the mean was
determined for each of the data sets (plotted as error
bars in the graphs), and P-values <0.05 between
compared samples were assigned statistical signiﬁcance.
Library screening and promoter sequence analysis
To isolate the mouse Nr2F1 promoter, a genomic library
(129SVJ Mouse Genomic Library in the Lambda FIX II
vector, Stratagene, CA) was screened. A PCR product
containing 1 kb of mouse Nr2F1 promoter sequence
was used as the probe for library screening. Positive
plaques were further screened three times, and phage
DNA was isolated using the Wizard kit (Promega, WI).
The positive clones were veriﬁed by sequencing a portion
of each clone. The inserts in the positive plaques were
cloned into the pGL3 ﬁreﬂy luciferase reporter plasmid
(Clontech, CA), and assayed for RA responsiveness.
This identiﬁed a 1 kb region as sufﬁcient for RA-induced
transcription. The fragment corresponded to a 1 kb region
of sequence located 2.4 kb upstream of the P3 RefSeq
transcriptional start site (TSS; genome coordinates, NCBI
bld 37, MM9, chr13:78339594-78340675).
Transient transfections and luciferase assays
F9 cells were transfected with luciferase reporter con-
structs containing different lengths of 50 ﬂanking se-
quences of the Nr2F1 gene using the Lipofectamine
method (Invitrogen, CA) (45). The reporter plasmid
pRL-TK (Renilla luciferase-thymidine kinase) (Promega,
WI) was used as control for transfection efﬁciency. Cells
were then cultured with or without RA for another 24 or
48 h. Fireﬂy and Renilla luciferase activities were
sequentially measured using the Dual-luciferase Reporter
Assay system (Promega, WI) with a luminometer.
ChIP assays
ChIP assays were performed as previously described
(22,46,47). In brief, a one-step ChIP protocol that uses for-
maldehyde cross-linking was employed for histone ChIP
assays. For Suz12, Ring1B and polII-CTD ChIP assays,
we used a two-step ChIP protocol. Cells were resuspended
in variable amounts of lysis buffer thereby normalizing for
differences in cell numbers between plates. ChIPs of
sonicated chromatin from 5.0 106 F9 cells were per-
formed with 2mg of antibody (Ab) per ChIP. Antibodies:
H3K27me3 (#07-449, Millipore, MA); H3K4me3 (#07-473,
Millipore, MA); H3K9/K14ac (#06-599, Millipore, MA);
Suz12 (#3737S-D39F6, Millipore, MA); Ring1B (48);
polII-CTD (#MMS-134R, Covance, NJ); Rabbit-IgG
(#sc-2027, Santa Cruz, CA). The primer sequences and
antibodies are listed in the Supplementary Table S2. Each
ChIP assay was performed at least three times starting with
independently propagated cells each time (n 3).
Western blots
The sodium dodecyl sulphate–polyacrylamide gel electro-
phoresis and western blot analyses were performed as
described (22,49) using primary antibodies for Suz12
(1:1000), H3K27me3 (1:5000) and H3K4me3 (1:2000),
and b-actin (1:80000, MAB1501, Millipore, MA), EZH2
(1:1000, 3147-AC22, Cell Signaling, MA), Nr2F1 (1:1000,
GTX114835, GeneTex, CA) and horseradish peroxidase
conjugated anti-rabbit secondary Ab (1:5000, sc-2030,
Santa Cruz, CA). Each Ab was diluted in PBS with 5%
Blotto (Biorad, CA) and 0.1% Tween-20. The membranes
were developed with Supersignal Substrate (Pierce, IL) for
5min and exposed to HyBlot ﬁlm (Denville Scientiﬁc, NJ).
Bioinformatics analyses
The gene location, exon–intron boundaries and TSSs
were speciﬁed in accordance with the NCBI Refer-
ence Sequences (50). Processed, mapped, next-generation
RNA-seq, ChIP-seq and DNA methylation/hydrox-
ymethylation data sets for undifferentiated and RA-
treated mouse ES cells were downloaded from the NCBI
Geo database (http://www.ncbi.nlm.nih.gov/geo/) and
viewed in the integrated genome viewer (IGV 2.0) (51).
Where appropriate the GALAXY implementation of the
UCSC liftover tool was used to convert genome coordin-
ates between mouse genome builds v36 (mm8) and
NCBI37 (mm9) (52).
RESULTS
Identification and cloning of the murine Nr2F1
(Coup-TF1) 50 flanking region
We determined the time-dependent increases in Nr2F1 and
Hoxa5 transcript levels in response to RA treatment of F9
WT embryonal carcinoma stem cells (Figure 1A).
We found that Nr2F1 transcript levels exhibit a
moderate/slow increase, with a half-maximal induction
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at 24 h, whereas Hoxa5 transcript levels increase dramat-
ically/rapidly in response to RA, with a half-maximal in-
duction at 12 h. Consequently, the induction of Nr2F1 is
delayed relative to that of Hoxa5. We have previously
shown that increased transcriptional activity of the
Hoxa-d clusters in response to RA is associated with
decreased PRC2 occupancy of the Hox promoters (23).
Therefore, we used ChIP to evaluate the levels of the
PRC2 core component protein Suz12 at the Nr2F1 and
Hoxa5 promoter regions in response to RA treatment of
F9 WT cells (Figure 1B). We found that the Suz12 levels at
the Nr2F1 promoter region increased during the ﬁrst 24 h,
and then declined to below the initial levels. In contrast,
the Suz12 levels decreased rapidly at the Hoxa5 promoter
region (Figure 1B).
To evaluate the involvement of the RA receptors
RARa, RARb2 and RARg, respectively, we next
assessed the Nr2F1 and Hoxa5 transcript levels in F9
RAR knockout cell lines devoid of individual RAR
isotypes (21,39–41,53). We found that 24 h of RA treat-
ment signiﬁcantly increased Nr2F1 transcript levels in F9
WT (4-fold). In the RAR2
/ and RAR/ cell lines,
Nr2F1 transcript levels were induced by RA to only 43
and 57% of WT levels, respectively (Figure 1C, left). In
contrast, the RAR/ cell line displayed Nr2F1 transcript
levels similar to those of WT (97%). For comparison, we
measured the increase in Hoxa5 transcript levels in
response to RA (Figure 1C, right). The Hoxa5 gene is
directly activated by RA in vivo and in cultured ES cells
(54). In F9 WT cells Hoxa5 transcript levels were potently
induced by 24 h of RA treatment (8-fold). Consistent
with Hoxa5 expression being dependent on RARb2 (54),
we found that Hoxa5 transcript levels were increased to
only 20% and 38% of WT levels following RA addition to
Figure 1. RA increases Nr2F1 and Hoxa5 transcript levels in F9 stem cells. (A) Nr2F1 and Hoxa5 transcript levels in untreated F9 WT cells and on
1, 8, 24, 48 and 72 h of RA treatment (1 mM). (B) ChIP analysis shows that the PRC2 core protein component Suz12 initially increases at the Nr2F1
promoter, but decreases at the Hoxa5 promoter in response to RA (RefSeq promoter regions). (C) Nr2F1 and Hoxa5 transcript levels in F9 WT and
in RARa, RARb2 and RARg knockout cells, untreated or treated with RA for 8 or 24 h. Statistical signiﬁcance (P< 0.05) is indicated for the effect
of RA (24 h RA relative to vehicle-treated cells), and for the effect of RAR knockout in 24 h RA treatment conditions (relative to WT). All
experiments were performed three or more times starting with fresh cells (n 3).
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the RAR2
/ and RAR/ cell lines, respectively
(Figure 1B). In contrast, the RAR/ cell line displayed
Hoxa5 transcript levels that were similar to WT (110%).
Therefore, we conclude that both RARg and RARb2 (or
downstream targets thereof) are required for the full RA-
associated increases in Nr2F1 and Hoxa5 transcript levels
to be achieved.
Deletion analysis of the Nr2F1 upstream region and
analysis of DNA methylation status
To identify DNA elements required for Nr2F1 transcrip-
tional activation, we isolated 14 kb of the mouse Nr2F1
locus from a phage library. The phage DNA that con-
tained portions of 50 Nr2F1 sequence (55) was digested
and fragments were assayed in the pGL3 reporter to
identify the DNA region(s) responsible for the RA induc-
tion. We identiﬁed a 1 kb region upstream of the RefSeq
TSS (P3, Figure 2A) as sufﬁcient to drive RA-dependent
transcription (data not shown). Importantly, this fragment
contains at least two previously identiﬁed TSS (P1 and P2,
Figure 2A) for the murine Nr2F1 gene (50,55).
To delineate the region responsible for the RA induc-
tion of Nr2F1, we generated further deletions of the RA
responsive 1 kb construct. Together with a series of shorter
deletion constructs, all of which contain the most
upstream promoter identiﬁed for Nr2F1 (P1), the 1 kb
construct was assayed for RA responsiveness in F9 WT
cells (Figure 2B). Using the Nr2F1 promoter numbering
system relative to the P1 promoter described by Salas and
colleagues (55), RA increased the reporter activity of the
441 bp promoter/luciferase construct by 3.4-fold
(Figure 2A). A 50-truncation to 382 bp reduced the RA
induction to <2-fold. Constructs with further deletions of
the Nr2F1 gene displayed no statistically signiﬁcant RA
induction (Figure 2B). These results suggest the presence
in Nr2F1 of an RA-inducible enhancer element (IEE) pos-
itioned at 383–441 bp upstream of the P1 promoter (2.4 kb
upstream of the P3 RefSeq promoter).
We next wanted to evaluate the functionality of the P1
promoter in ES cells. Using publically available RNA-seq
data, we performed bioinformatic analysis of transcription
in RA-treated ES cells (Figure 2C). This analysis revealed
transcriptional activity upstream of the Nr2F1 RefSeq
promoter (P3), thereby conﬁrming upstream promoter
activity also in ES cells. Interestingly, Nr2F2 displayed
similar transcriptional activity upstream of the RefSeq
promoter, whereas both Hoxa5 and Cyp26a1 displayed
only background levels of transcription upstream of
their respective RefSeq promoters (Figure 2C).
DNA methylation, which occurs at CpG dinucleotides,
is an epigenetic modiﬁcation that can potently repress
transcription. Regulation by DNA methylation is particu-
larly pronounced in genes with CpG-rich promoter
regions. We therefore evaluated the CpG content
proximal to the RefSeq TSS of Nr2F1, Nr2F2, Hoxa5
and Cyp26a1. The 1000 bp regions upstream of the
RefSeq TSS of Nr2F1 and Nr2F2 displayed a higher
density of CpG dinucleotides (100 CpGs) as compared
with the Hoxa5 and Cyp26a1 promoters, which possess a
modestly lower CpG density (57 and 52, respectively) as
compared with a random 1000 bp sequence (62 CpGs)
(Figure 2C). As promoter proximal CpG sites are
commonly regulated by DNA methylation, we evaluated
the DNA methylation status of candidate regions in the
Nr2F1 gene. We found that the Nr2F1 IEE (P1/P2) and
the RefSeq promoter (P3) displayed only minimal DNA
methylation both before and after RA treatment of F9
WT cells (Supplementary Figure S2). Thus, changes in
DNA methylation are not involved in the changes in
Nr2F1 transcript levels after RA addition.
RA modifies histone marks and PRC association with the
Nr2F1 and Hoxa5 genes
We next examined the effects of RA on the epigenetic
signatures at the Nr2F1 gene in F9 embryonal carcinoma
stem cells. As discussed above, three distinct Nr2F1 TSSs
have been detected in differentiating ES cells (Figures 2C
and 3A). We measured the levels of both permissive and
repressive histone marks at the IEE (P1/P2) and the
RefSeq promoter (P3). To compare Nr2F1 with a previ-
ously identiﬁed direct target of RA, we analyzed the epi-
genetic marks at the Hoxa5 proximal promoter and
retinoic acid response element (RARE) in parallel (54).
We found that in F9 WT cells there was an RA-depend-
ent, >2-fold increase in the levels of Suz12 both at the IEE
and at the RefSeq promoter (P3) of the Nr2F1 gene,
whereas Suz12 levels were decreased at the Hoxa5 gene
(Figure 3B, left). We observed parallel changes in the
PRC2-associated H3K27me3 mark and in the levels of
Ring1B, a core component of the PRC1 repressive
complex, at both the Nr2F1 and the Hoxa5 genes
(Figure 3B, left). Notably, for the Nr2F1 gene, the
increase in response to RA was observed at both the
RefSeq promoter (P3) and the IEE (P1/P2). Similarly,
RA-associated increases in the PRC repressive epigenetic
marks occurred in the three F9 RAR knockout lines,
RAR/, RAR2
/ and RAR/ at the Nr2F1 gene
(Figure 3B, right). To ascertain that RA was not perturb-
ing the PRC2, we evaluated the association of Suz12 with
the PRC2 catalytic subunit EZH2 (Supplementary Figure
S3). We found that RA had no effect on the overall inter-
action between Suz12 and EZH2 core components.
Transcriptional activation is often associated with a
decrease in epigenetic repressive marks, as we observed
for the Hoxa5 gene (Figure 3B, left), and for Cyp26a1,
Hoxa1 and RAR2 genes (22). Despite the increased
levels of PRC repressive marks at the Nr2F1 RefSeq
promoter (P3) and IEE (P1/P2) after RA addition, we
observed an increase in Nr2F1 transcript levels in
response to RA (Figure 1A and C).
We next examined the H3K9/K14ac and H3K4me3
histone modiﬁcations associated with transcriptional acti-
vation and the levels of Ser5-phosphorylated (transcrip-
tionally poised) RNA polymerase II (polII-CTD). The
Nr2F1 RefSeq promoter (P3) displayed increased levels
of the H3K9/K14ac and H3K4me3 marks (1.9-fold and
2.1-fold, respectively) on RA treatment of F9 WT cells
(Figure 3C, left). Likewise, a 2-fold increase in the polII-
CTD level was detected at the Nr2F1 RefSeq promoter
(P3) on a 24 h RA treatment of F9 WT cells (Figure 3C,
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Figure 2. RA responsiveness of the upstream Nr2F1 promoter region in F9 stem cells. (A) Schematic diagram of the murine Nr2F1 genomic region.
RNA transcripts are shown at the top with exons marked by boxes (coding region in gray). Putative promoters are depicted by angled arrows in the
genomic map. The most upstream promoter of the mouse Nr2F1 is speciﬁed by a circled arrow. PCR amplicons are marked below (sizes speciﬁed in
base pairs). Note that for the RT-primers the sizes of both cDNA and gDNA amplicons are indicated. (B) RA responsiveness of different regions
proximal to the most upstream promoter of the mouse Nr2F1. The numbers refer to the 50 terminal nucleotide included in each construct with respect
to the upstream transcription start site (P1-TSS). The nucleotide sequence of the 441 to 382 region, which is required for a potent RA induction
(>2-fold), is shown at the bottom of the ﬁgure. Note that in the bar diagram only constructs with the P1-TSS located proximal to the luciferase
coding region are shown. Luciferase (ﬁreﬂy) reporter constructs containing the indicated regions of the Nr2F1 sequence were transfected into F9 WT
cells, and assayed for RA responsiveness. Relative luciferase activities were expressed as a ratio over the untreated F9 WT cells transfected for each
promoter construct, and statistical signiﬁcance was determined. Data are compiled from at least three independent experiments. **P< 0.05.
(C) Transcriptional activity at the Nr2F1, Nr2F2, Hoxa5 and Cyp26a1 genes assessed in publically available RNA sequencing data set generated
from mouse ES (CCE) cells treated with RA for 5 days (GSM566812) (56). The number of CpG dinucleotides within the 1000 bp sequence upstream
of the RefSeq promoter is indicated in the left side of the ﬁgure. The Nr2F1, Nr2F2, Hoxa5 and Cyp26a1 reference transcripts are indicated as blue
boxes below the RNA-seq intensity data (white arrow heads). Notice the high transcriptional activity extending >1 kb upstream of the Nr2F1 and
Nr2F2 reference sequence TSSs (P3). This contrasts with the low transcriptional activity upstream of the Hoxa5 and Cyp26a1 reference sequence
TSSs. The genomic location relative to the RefSeq TSS is indicated at the bottom.
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Figure 3. Chromatin Signatures of Nr2F1 and Hoxa5 in F9 WT and RAR knockout cells. (A) Schematic of Nr2F1 IEE and promoter regions. Nr2F1 putative TSSs are indicated by angled
arrows (P1, P2 and P3). The proximal nucleotide sequences are shown for the Nr2F1 promoter and IEE region, and the putative enhancer element is underlined. The GC content of the evaluated
regions is illustrated in the background graphs, with CpG islands marked in gray. Note the local depletion of CpGs proximal to the Nr2F1 RefSeq promoter (P3). White arrows indicate genomic
regions included in the Nr2F1 reporter constructs (Fig. 2B, 0.5 and 1.0 kb, respectively). The gray bars specify primary transcripts from the indicated TSSs. (B) ChIP analysis shows that
Polycomb repressive marks (Suz12, H3K27me3 and Ring1B) decrease at the Hoxa5 promoter and RARE, but increase at the Nr2F1 promoter and IEE in F9 WT cells in response to a 24 h RA
treatment (left, boxed). Similar patterns of Nr2F1 epigenetic changes were observed in RAR knockout cells (KO, right). (C) ChIP analysis shows that transcriptional permissive marks (H3K9/
K14ac, H3K4me3 and polII-CTD) increase at the Hoxa5 promoter and RARE, and at the Nr2F1 promoter and IEE in response to a 24 h RA treatment (left). Similar patterns of Nr2F1
epigenetic changes were observed in RARa knockout cells, whereas H3K9/14ac levels did not increase in RARb2 and RARg knockout cells (right). (D) ChIP analysis shows Histone 3 occupancy
(H3) and the non-speciﬁc background signal (IgG). The ChIP signals are depicted relative to the total chromatin input in each ChIP. Statistical signiﬁcance (P< 0.05) is indicated by asterisks for
the effect of RA, (n.s.: non-signiﬁcant).
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left). In contrast, we observed only modest changes (<1.5-
fold) in the levels of polII-CTD and in the levels of the
permissive marks H3K9/K14ac and H3K4me3 at the
Nr2F1 IEE in response to RA treatment (Figure 3C,
left). Consequently, the RA-associated increase in tran-
scriptionally permissive marks was more pronounced at
the RefSeq promoter (P3) than at the IEE (P1/P2) of the
Nr2F1 gene. At the Hoxa5 gene, we observed an RA-
associated increase in the H3K9/K14ac mark at the
promoter and RARE (1.6- and 1.8- fold, respectively),
and a large increase in polII-CTD association (>5-fold)
with the promoter and the RARE (Figure 3C, left). Also
RA-associated increases in the H3K4me3 mark at the
promoter and RARE (1.2- and 1.4- fold, respectively)
were detected at the Hoxa5 promoter and RARE
(Figure 3C, left). We observed an RA-associated
increase in the levels of H3K9/14ac in RARa knockout
cells, whereas the H3K9/14ac levels did not increase in
RARb2 and RARg knockout cells (Figure 3C, right).
The RA-associated increases in H3K4me3 and polII-
CTD at the Nr2F1 gene in the RAR knockout cells were
similar to those observed in F9 WT cells (Figure 3C). The
histone density at the Nr2F1 gene was not affected by RA,
whereas RA led to nucleosomal depletion at the Hoxa5
gene (Figure 3D, bottom). We conclude that the increase
in Nr2F1 transcriptional activity following a 24 h RA
treatment of F9 WT cells occurs even when epigenetic re-
pressive factors such as Suz12, Ring1B and the
H3K27me3 mark are present in Nr2F1 regulatory regions.
Suz12 knockdown reveals that RA differentially regulates
the transcription of Nr2F1 and Hoxa5 genes
The RA-induced changes in PRC association with the
Nr2F1 promoter were dramatically different from those
of the Hoxa5 promoter (Figures 1B and 3B), yet both
genes display increased transcriptional activity in response
to RA (as evident by increased promoter association with
permissive histone marks and by increased transcript
levels). To deﬁne further the role of the Suz12 protein, a
key protein component of the PRC2 polycomb repressive
complex, we generated knockdown stem cell lines depleted
of Suz12 transcripts. We performed the shRNA-induced
Suz12 depletion in the F9 WT cell line and in each of the
RAR knockout cell lines. Western blot analyses conﬁrmed
that the levels of Suz12 protein (and the levels of K27me3
modiﬁed histone 3) in each of the Suz12 knockdown lines
were reduced by >90% relative to each of the shLuc
(control) transfected parent cell lines (Figure 4). We then
evaluated the effects of Suz12 depletion on Nr2F1, Nr2F2,
Hoxa5 andHoxa1 transcript levels in each of these cell lines
after 24h of RA treatment. The Suz12 depletion increased
the RA-responsiveness of Nr2F1 and Nr2F2 in F9 WT,
whereas we detected no signiﬁcant effects on the RA-
responsiveness of Hoxa5 and Hoxa1 (Figure 4). In the
RAR knockout lines, we observed similar effects of Suz12
depletion on these four genes (Figure 4).
We next examined the effects of Suz12 depletion on
additional RA responsive genes in WT ES cells. We
found that the knockdown of Suz12 by shRNA technol-
ogy dramatically increased the Nr2F1, Nr2F2, Meis1,
Sox9 and BMP2 transcript levels in response to RA
(Figure 5A). In contrast, Hoxa1, Hoxa5, Cyp26a1,
Cyp26b1 and RAR2 transcript levels were not signiﬁ-
cantly affected by the Suz12 depletion in both control
and RA-treated cells (Figure 5A). The levels of Suz12
transcripts in ES cells stably transfected with shSuz12 con-
structs were signiﬁcantly reduced compared with the levels
in shLuc (control) transfected ES cells (Figure 5B). As
expected, the transcript levels of the 36B4 reference gene
did not change in response to RA (Figure 5B). An RA-
dependent increase in Nr2F1 protein was observed on
Suz12 depletion, whereas the levels in control cells were
below detection (Figure 5C). The western blot analysis
also conﬁrmed that the total levels of Suz12 protein do
not change in response RA. Furthermore, the Suz12
knockdown reduced protein levels by >90% relative to
control ES cells (Figure 5C). The depletion of Suz12
also reduced the levels of EZH2 protein (Figure 5C).
Overall, our data suggest differential PRC2 dynamics in
RA-induced transcription of the Nr2F1, Nr2F2, Meis1,
Sox9 and BMP2 genes versus Hoxa5, Hoxa1, Cyp26a1,
Cyp26b1 and RAR2 genes. Speciﬁcally, Suz12 exhibits an
inhibitory effect on the RA-associated increases in Nr2F1,
Nr2F2,Meis1, Sox9 and BMP2 transcript levels, but not on
the RA-associated increase in Hoxa5, Hoxa1, Cyp26a1,
Cyp26b1 and RAR2 transcript levels (Figure 5A).
Importantly, whereas the Nr2F1 promoter shows increased
PRC2 association on RA treatment (Figures 1B and 3B),
the Hoxa5, Hoxa1, Cyp26a1 and RAR2 promoters all
respond to RA addition by dissociation of the PRC2 com-
ponent (Figures 1B and 3B and previous publications), thus
potentially explaining the more rapid transcriptional induc-
tion by RA of this latter group of genes.
In Silico ChIP-seq analysis of RARc, RXRa and RNA
polII association in F9 WT cells
A recently published ChIP-seq analysis of RARg, RXRa
and RNA polII in F9 WT cells (57) allowed us to expand
our analysis of the epigenetic signature of RA responsive
genes. We analyzed the RARg, RXRa and RNA polII
chromatin association with the PRC2-attenuated RA
target genes Nr2F1, Nr2F2 and Sox9, and with the non-
attenuated RA target genes Hoxa5 and Cyp26a1 at
various time points (Supplementary Figure S4). The
ChIP-seq analysis conﬁrmed recruitment of RNA polII
to the Nr2F1, Nr2F2, Sox9, Hoxa5 and Cyp26a1
proximal promoter regions in response to RA treatment
(Supplementary Figure S4). Importantly, with respect to
Hoxa5 and Cyp26a1, RNA polII was not only recruited
to the proximal promoter regions in response to RA but
was also detected distributed throughout the length of
each gene, consistent with highly active transcription. In
contrast, recruitment of RNA polII appeared to be lower
at both the promoters (as observed in Figure 3C) and
throughout the Nr2F1, Nr2F2 and Sox9 genes in the
presence of RA (Supplementary Figure S4).
The co-localization of RARg and RXRa at speciﬁc
genomic locations is strong evidence for an RARE.
Indeed, the ChIP-seq analysis conﬁrmed the previously
identiﬁed RAREs in Hoxa5 and Cyp26a1 (indicated in
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Supplementary Figure S4). The Cyp26a1 distal RARE
showed association with both RARg and RXRa,
whereas the proximal RARE was predominantly
associated with RXRa. This may indicate that the
proximal RARE is primarily bound by RARa or
RARb, whereas the distal RARE is primarily bound by
RARg. Neither RARg nor RXRa was associated with the
Nr2F1, Nr2F2 and Sox9 genes (Supplementary Figure S4).
This suggests that Nr2F1, Nr2F2 and Sox9 are secondary
targets in the RA signaling cascade. Alternatively, Nr2F1,
Nr2F2 and Sox9 could be targeted by different RAR and
RXR isotypes (e.g. RARa or RARb dimerized with
RXRb or RXRg).
DISCUSSION
In the current study, we have identiﬁed a novel class of
PRC target genes, represented by Nr2F1, Nr2F2, Meis1,
Sox9 and BMP2, that is activated during RA-induced
stem cell differentiation. The RA-associated
transcriptional activation of Nr2F1 occurs along with
both increases in PRC and H3K27me3 repressive marks
and permissive histone marks such as H3K4me3. The dif-
ferential effects of Suz12 depletion on Nr2F1/Nr2F2 and
Hoxa5/Hoxa1 (Figures 5 and 6) point to PRC2 dynamics
as a distinguishing feature between the canonical direct
RA target genes (rapidly induced) and a class of
attenuated RA target genes (slowly induced). PRC2 was
identiﬁed as a repressor of Hox gene transcription in
Drosophila (58,59). It it was thus somewhat surprising
that functional depletion of PRC2 in murine ES cells
did not enhance transcription activation of Hoxa1 (61)
or Hoxa5 (Figure 4). The functional characterization
of PRCs is further complicated by the variable PRC
complex composition and the numerous PRC target
genes (62,63). Several groups have evaluated individual
polycomb components (10,64), and Pasini et al. estab-
lished a role for the Suz12 polycomb protein in ES cell
differentiation (8). They further identiﬁed distinct groups
of PRC-regulated genes: (i) genes expressed in pluripotent
Figure 4. shRNA-mediated Suz12 knockdown increases Nr2F1 and Nr2F2 transcript levels. In F9 cells, Suz12 protein and transcript levels (upper
left and upper right, respectively) are reduced below detection and to 10%, respectively, by expression of a Suz12-speciﬁc shRNA. The Suz12
knockdown eliminates the PRC2-speciﬁc histone mark (H3K27me3), but has only a limited effect on the permissive H3K4me3 mark (western blot,
upper left). The Suz12 knockdown increases Nr2F1 (middle left) and Nr2F2 (bottom left) transcript levels (24 h RA treatment) by quantitative
RT-PCR, but has no effect on Hoxa5 (middle right) and Hoxa1 (bottom right) transcript levels. Statistical signiﬁcance is indicated by double asterisk
for the effect of RA (relative to vehicle-treated cells), and by asterisk for the effect of Suz12 knockdown in RA-treated conditions (48 h, relative to
shLuc control cells).
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ES cells and silenced in differentiated cells, (ii) genes tran-
scriptionally activated on differentiation and (iii) genes
that were initially activated and then silenced in
differentiated cells. This classiﬁcation was corroborated
by a recent report in which Mendoza-Parra et al. distin-
guished between (i) genes silenced by RA, (iia) genes
rapidly induced by RA and (iib) genes exhibiting
delayed induction by RA (57). This genome-wide ChIP-
seq study involved algorithm-based grouping of RA re-
sponsive genes, thereby providing a blinded validation of
the grouping. The emerging consensus is that genes ex-
pressed after differentiation show strong polycomb
protein association in the pluripotent stem cell state,
whereas genes expressed in stem cells show strong
polycomb association in the differentiated state (8,57).
Our ﬁndings, however, reveal that this broad consensus
does not ﬁt genes that display a delayed induction in
response to RA (e.g. Nr2F1 and Nr2F2). We show here
that such genes initially display an increase in PRC2
levels concurrent with transcriptional activation. We
demonstrate that PRC2 attenuates transcription of
Nr2F1 and describe the associated epigenetic changes
(Figures 4–6). This provides new mechanistic insights
into genes exhibiting delayed induction by RA i.e.
Nr2F1 (iib) and genes rapidly induced by RA i.e. Hoxa5
(iia) during stem cell differentiation.
To understand better the regulatory regions and chro-
matin environment of the Nr2F1 gene, we compared the
local epigenetic contexts of the Nr2F1 and Nr2F2 genes
with those of Cyp26a1 and Hoxa5. The Nr2F1, Nr2F2,
Cyp26a1 and Hoxa5 genes are embedded within bivalent
chromatin regions associated with CpG islands (Figure 3
and Supplementary Figure S5), as is typically seen for
genes, with the potential for transcriptional activation or
repression depending on the ES cell differentiation state
(4,65). The Nr2F1 and Nr2F2 promoter regions are
enriched for CpG sites relative to the Cyp26a1 and
Hoxa5 promoter regions (Figure 2C). Mammalian pro-
moters show a bimodal distribution based on CpG
content (66,67), and blinded computational analyses
have conﬁrmed that key epigenetic histone marks differ
among promoters of high versus low CpG content (68).
Figure 5. The response to Suz12 depletion distinguishes two classes of RA-inducible genes. (A) In ES cells, Suz12 depletion increases Nr2F1, Nr2F2,
Meis1, Sox9 and BMP2 transcript levels (upper panel), but has no effect on Hoxa5, Hoxa1, Cyp26a1, Cyp26b1 and RAR2 transcript levels (lower
panel) on RA treatment. Transcripts were measured by quantitative RT-PCR. Statistical signiﬁcance is indicated by double asterisk for the effect of
RA (relative to vehicle-treated cells), and by asterisk for the effect of Suz12 knockdown in RA-treated cells (48 h, relative to shLuc control cells). (B)
Suz12 transcript levels are diminished by expression of a Suz12-speciﬁc shRNA, whereas transcript levels of the 36B4 reference gene are unaffected.
(C) The levels of Nr2F1 protein are elevated on Suz12 depletion and increase in an RA-dependent manner by western blotting. The levels of
Polycomb proteins Suz12 and Ezh2 are reduced on depletion of Suz12, whereas actin levels remain unchanged by western blotting. Western blots
were performed at least three times with different cell extracts; a representative blot is shown.
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RA resulted in enrichment of PRC proteins at the Nr2F1
promoter (high CpG content), but resulted in a decrease in
PRC proteins located at the Hoxa5 promoter (low CpG
content). This difference could be related to the presence
or absence of a TATA-box, which speciﬁes a distinct TSS
only in promoters with low CpG content (69). The obser-
vation that Nr2F1 and Nr2F2 use loosely deﬁned TSSs,
whereas Cyp26a1 and Hoxa5 each uses a clearly deﬁned
TSS (Figure 2C), further supports this grouping of genes
into different functional classes.
Differences in the epigenetic environment of the Nr2F1/
Nr2F2 versus the Cyp26a1/HoxA5 genes in untreated con-
ditions could potentially explain the differential response
to RA, i.e. slow versus rapid induction (Figure 1A). In the
absence of RA (untreated ES cells), Nr2F1, Nr2F2,
Cyp26a1 and HoxA5 are transcriptionally silent (Figure
5). We therefore compared the epigenetic signatures in
untreated ES cells using publicly available ChIP-seq data
(Supplementary Figure S4). The key role of PRC2
(Figures 1B and 3B) prompted us to further evaluate
PRC2 associated epigenetic marks (H3K27me3, EZH2,
Suz12 and Ring1B) and H3K4 methylation of Nr2F1,
Nr2F2, Cyp26a1 and HoxA5 genes. Our bioinformatics
analysis suggests that in the absence of RA, the epigenetic
distribution of H3K27me3 and PRC1/2 is lower at the
Nr2F1 and Nr2F2 genes in comparison with the
Cyp26a1 and HoxA5 genes in ES cells. The RefSeq
promoter regions of Nr2F1 and Nr2F2 show a localized
decrease of H3K27me3 on either side of the TSS, which
extends to a localized decrease in H3K4 methylation. In
contrast, in the absence of RA, the Hoxa5 and Cyp26a1
proximal promoter regions show high levels of H3K27me3
and H3K4me3 and decreased H3K4 methylation proximal
to the TSS, which may be the result of nuclesome deple-
tion around the TSS. Interestingly, RNA-seq data
(Figure 2C) suggest that whereas the TSSs of Hoxa5 and
Cyp26a1 are clearly deﬁned, Nr2F1 and Nr2F2 each may
use a number of alternative sites for transcriptional initi-
ation. Consistent with these data, the RA responsive
region of Nr2F1 (IEE, Figure 2) is enriched for the
H3K4me1 modiﬁcation (70), progressively transitioning
on RA addition to H3K4me2/3, which co-localizes
with H3K27me3 and Jarid2a upstream of the TSS
(Supplementary Figure S4). These features are similar to
the features recently described for PRC-associated permis-
sive enhancers (14), which permit cell type–speciﬁc tran-
scriptional activation of PRC-repressed stem cell genes
depending on the promoter context. The attenuated induc-
tion of Nr2F1 may involve recruitment of Ring1B and/or
Jarid2, which has been reported to introduce pausing of
polII at loci primed for future transcriptional activation
(64,71). Indeed, we found that Ring1B was recruited to the
IEE and RefSeq promoter of Nr2F1 in response to RA
(Figure 3B). The RAR2 and RAR knockout cell lines
displayed reduced induction of Nr2F1 by RA (Figure 1C).
However, polII was recruited even more efﬁciently in
RAR/ cells than in WT cells (Figure 3C, right). One
explanation could be that the absence of RARb2 reduces
polII recruitment, whereas the absence of RARg affects
the initiation of transcriptional elongation. The RA-
associated increase in H3K4me3 levels observed at the
Nr2F1 gene in both the RARb2 and RARg knockout
cell lines suggests that RA induces a partially permissive
chromatin structure (Figure 3C). In contrast, we observed
no increase in H3K9/14ac levels at the Nr2F1 gene in the
RARb2 and RARg knockout cell lines, which suggests
that histone acetylation is required for full transcriptional
activation of Nr2F1.
The role of Nr2F1 in RA-associated endodermal differ-
entiation of ES cells (35) and the potential of RA to
function as a ligand for Nr2F2 (37), and as a regulator
of mesenchymal differentiation (38) point to the Coup-
TFs as key players in RA-induced differentiation. Nr2F1
basal transcription is mediated by three ETS response
Figure 6. Summary model of Nr2F1 and Hoxa5 epigenetic signatures
in response to RA. Nr2F1 and Hoxa5 display different epigenetic sig-
natures on RA treatment of stem cells. Nr2F1 is characterized by
increased levels of PRC (Suz12 and Ring1B) and the associated
H3K27me3 histone mark in response to RA. In contrast, the Hoxa5
epigenetic signature is characterized by dissociation of PRC (Suz12 and
Ring1B) and reduction of the H3K27me3 histone mark. Note that the
epigenetic signatures of Hoxa5 are similar in presence and absence of
Suz12 after RA addition. In contrast, the epigenetic signature of Nr2F1
on RA treatment differs in the presence and absence of Suz12, thus
potentially explaining the increased transcriptional activity on Suz12
knockdown. For both Nr2F1 and Hoxa5, the transcriptional induction
is marked by increased levels of H3K4me3, H3K9ac and H3K14ac
permissive histone marks. The different marks are depicted as shapes
whose sizes reﬂect the relative abundance in the speciﬁed condition.
Histone H3 is depicted as a gray circle. PRC1 and PRC2 are repre-
sented by Ring1B and Suz12, respectively.
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elements (55), yet the DNA elements within the Nr2F1
promoter that mediate the RA responsiveness of Nr2F1
are unknown (27,34). The Nr2F1 promoter region
contains no consensus RARE (DR2 or DR5), and thus
far no functional element has been identiﬁed that can
explain the RA responsiveness of Nr2F1 (Supplementary
Figure S4). This is the ﬁrst study identifying the Nr2F1
promoter region that is responsible for the RA induction.
The complex dynamics of PRC association in response to
RA suggest that several transcription factors cooperate to
regulate the transcription of the Nr2F1 gene. Thus, it will
be important to identify the cis-regulatory DNA elements
responsible for the RA-associated PRC recruitment and to
characterize the transcription factors that recognize these
DNA elements.
Here we identify PRC2 dynamics as a distinguishing
feature between two classes of PRC2 target genes repre-
sented by the Nr2F1 (Coup-TF1) and the Hoxa5 gene,
respectively. We conclude that PRC1/2, in addition to
specifying transcriptional repression, can function to
attenuate transcriptional activation by RA of speciﬁc
genes during stem cell differentiation. Attenuation of the
maximal transcriptional activation may allow for more
exquisite precise regulation of commitment to a speciﬁc
differentiation pathway.
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SUPPLEMENTARY INFORMATION 
 
ABBREVIATIONS 
cDNA:  complementary DNA 
Coup-TF: Chicken Ovalbumin Upstream Promoter-Transcription-Factor 
ES:  Embryonic Stem 
gDNA: genomic DNA 
H3K27me3: Trimethylated Histone 3 Lysine 27 
H3K4me3: Trimethylated Histone 3 Lysine 4 
IEE:  Inducible Enhancer Element 
NR2F1: Nuclear Receptor 2F1 
PCR:  Polymerase Chain Reaction 
PRC:  Polycomb Repressive Complex 
RA:  all-trans Retinoic Acid 
RAR:  Retinoic Acid Receptor 
RARE: Retinoic Acid Responsive Element 
RefSeq: NCBI Reference Sequence 
RT:  Reverse Transcription 
RXR:  Retinoid X Receptor 
shRNA: short hair-pin RNA 
TSS:  Transcriptional Start Site 
WT:  Wild-Type 
 
FIGURE LEGENDS 
 
Figure S1. Genotypic validation of F9 RAR knockout cell lines.  
Transcript levels were assessed in triplicate samples after 0, 8 and 24 hours treatment with RA. 
The RAR isoform and PCR band sizes are indicated to the left of the gel. Note the RARβ2 is itself 
induced by RA. The truncated transcripts detected in RARα and RARγ knockout cell lines, 
respectively, represent nonsense coding mRNAs resulting from the genomic manipulations. The 
three F9 RAR knockout cell lines were all generated by former lab members (Boylan et al., 
1993; Boylan et al., 1995; Faria et al., 1999). 
 
Figure S2. CpG methylation of Nr2F1 RARE and promoter regions. The CpG methylation is 
scarce at the enhancer and at the promoter regions of Nr2F1 both in the absence (blue) and in the 
presence (red) of RA. Each horizontal line represents the methylation status of an independent 
allele. The numbers below the figures indicate the CpG position relative to the PRefSeq 
transcriptional start site (+1). 
 
Figure S3. Co-IP of PRC2 core components Ezh2 and Ezh1. Suz12 interacting proteins were 
immunoprecipitateded using a Suz12 directed antibody and detected by Western blot analysis. 
Ezh2 but not Ezh1 associated with Suz12. Note that the Ezh1 bands in the Suz12 IP had 
intensities similar to those in the IgG negative control (background levels). 
 
Figure S4. The Effect of RA on RARγ, RXRα, and PolII association with Nr2F1, Nr2F2, 
Sox9, Hoxa5, and Cyp26a1. RARγ, RXRα, and PolII association were characterized using 
publically available genome wide chromatin immunoprecipitation assays coupled with next 
generation DNA sequencing datasets (ChIP-seq). (A) Nr2F1, (B) Nr2F2, (C) Sox9, (D) Hoxa5, 
and (E) Cyp26a1 genomic loci in mouse F9 stem cells. ChIP-seq for untreated (0 h RA) and RA 
treated F9 cells (6 h and 48 h RA) are shown for RARγ (purple), RXRα (green), and RNA polII 
(blue). Each read is aligned to the corresponding genomic location, thereby visualizing specific 
chromatin association as density of reads. RefSeq intron and exon locations are specified in blue 
at the bottom of each alignment. Chromosome coordinates and scale bars are located at the top of 
each alignment. 
 
Figure S5. The Epigenetic signatures of Nr2F1 and Hoxa5. Histone modifications and PRC 
component association were characterized using publically available genome wide  chromatin 
immunoprecipitation assays coupled with next generation DNA sequencing datasets (ChIP-seq). 
(A) Nr2F1, (B) Nr2F2, (C) Hoxa5 and (D) Cyp26a1 genes in mouse embryonic stem cells. 
Accession numbers for datasets used were for ChIPseq: GSE30538 (F9 RARγ, F9 RXRα, F9 Pol 
II); GSE12241 (ES H3K4me3, ES H3K27me3, ES RNA pol II); GSE11172 (ES H3K4me1, ES 
H3K4me2); GSE13084 (PRC proteins, ES Suz12, ES EZH2, ES Ring1B); GSE24165 (ES 
H3K27ac); GSE465889 (Jarid2). RNAseq: mRNA expression analysis of RA differentiated 
mouse ES cells GSM566812. DNA methylation and hydroxymethylation state: GSE28682. 
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Table 1: Gene Expression Primers 
 
Forward Sense primer (5Õ-3Õ) Reverse Antisense primer (5Õ-3Õ) Product (bp) 
Induced by RA   cDNA gDNA 
mBMP2(+)A CTTAGACGGACTGCGGTCTCCTA mBMP2(-)B ACGTCTTCCGAAGGCCGGGACA 171 1238 
mCyp26a1(+)A GAAACATTGCAGATGGTGCTTCAG mCyp26a1(-)B CGGCTGAAGGCCTGCATAATCAC 272 728 
mCyp26b1(+)A TGGACTGTGTCATCAAGGAGGT mCyp26b1(-)B GTCGTGAGTGTCTCGGATGCTA 143 492 
mHoxa1(+)E TAACTCCTTATCCCCTCTCCAC mHoxa1(-)D ACCCACGTAGCCGTACTCTCCA 151 628 
mHoxa5(+)C CCCCTGGATGCGCAAGCTGCACATT mHoxa5(-)F TTCTCCAGCTCCAGGGTCTGGTAGCGA 105 1062 
mMeis1(+)A CATGATAGACCAGTCCAACC mMeis1(-)D GGCTACATACTCCCCTGGCATACT 243 3827 
mNR2F1(+)G CTGTCCCATCGACCAGCACCACCG mNR2F1(-)H GACAGGTAGCAGTGGCCATTGAGAG 177 2607 
mNR2F2(+)C GAAGATGCAAGCGGTTTGGGAC mNR2F2(-)D GGCAAACTGCCCGTGGGT 100 7908 
mSox9(+)C AGTACCCGCATCTGCACAAC mSox9(-)D TACTTGTAATCGGGGTGGTCT 145 938 
mSuz12(+)A CGGCCACAAGAAATGGAAGTAGATA mSuz12(-)B TGCTGCATTTCTCGGAGCTT 335 2753 
m36B4(+)A AGAACAACCCAGCTCTGGAGAAA m36B4(-)B ACACCCTCCAGAAAGCGAGAGT 448 629 
Genotyping      
mRARαE34(+) TGGCTCAAACCACTCCATCGAGA mRARαE6(-) CCTGGTGCGCTTTGCGAACC 425 n/a 
mRARβE3a(+) GCAGCACCGGCATACTGCTC mRARβE4(-) CACTGACGCCATAGTGGTA 155 26450 
mRARγ2A(+) tttcaattgCCatgTACGACTGCATGGAATCGT mRARγE7(-) TTGCTGACCTTGGTGATGAGTT 551 6031 
 
 
 
Table 2: ChIP primers 
 
Forward Sense primer (5Õ-3Õ) Reverse Antisense primer (5Õ-3Õ) Product Position 
mNR2F1-p(+)M TGCCGCCTGTGCCATTTCTGAT mNR2F1-p(-)P CAGCGAGCGAGCTCCCTTCTCT 73 -70;+3 
mNR2F1-E(+)A GTCTTCTCGTTCGTTCGTTTGCTCTT mNR2F1-E(-)B CCTCATATTGTTGTGGGGCGGCT 277 -850;-773 
mHoxa5-p(+)G GCCATAATGGGCTGTAACCTCA mHoxa5-p(-)H ACCCGTTGCCGCCGTTCAGT 120 -160;-140 
mHoxa5-R(+)A CCTGAAGCTCAGTGCTGTGTATCT mHoxa5-R(-)B CTGTCTGGGCAGATGACTAAGAG 112 +7487;+7599 
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cDNA:  complementary DNA 
Coup-TF: Chicken Ovalbumin Upstream Promoter-Transcription-Factor 
ES:  Embryonic Stem 
gDNA:  genomic DNA 
H3K27me3: Trimethylated Histone 3 Lysine 27 
H3K4me3: Trimethylated Histone 3 Lysine 4 
IEE:  Inducible Enhancer Element 
NR2F1: Nuclear Receptor 2F1 
polII:  RNA polymerase 2 
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RefSeq: NCBI Reference Sequence 
RT:  Reverse Transcription 
RXR:  Retinoid X Receptor 
TSS:  Transcriptional Start Site 
WT:  Wild-Type 
 
 
FIGURE LEGENDS 
 
Figure S1. Genotypic validation of F9 RAR knockout cell lines.  
Transcript levels were assessed in triplicate samples after 0, 8 and 24 hours treatment with RA. The RAR 
isoform and PCR band sizes are indicated to the left of the gel. Note that RARβ2 is itself induced by RA. The 
truncated transcripts detected in RARα and RARγ knockout cell lines, respectively, represent nonsense coding 
mRNAs resulting from the genomic manipulations. The three F9 RAR knockout cell lines were all generated by 
former lab members (39-41). 
 
Figure S2. CpG methylation of Nr2F1 RARE and promoter regions. The CpG methylation is low at the 
enhancer and at the promoter regions of Nr2F1 both in the absence (blue) and in the presence (red) of RA. 
Each horizontal line represents the methylation status of an independent allele. The numbers below the figures 
indicate the CpG position relative to the PRefSeq transcriptional start site (+1). 
 
Figure S3. Co-IP of PRC2 core component Ezh2. Suz12 interacting protein Ezh2 was immunoprecipitated 
using a Suz12 directed antibody and detected by Western blot analysis. Ezh2 associated with Suz12.  
 
Figure S4. The Effect of RA on RARγ, RXRα, and PolII association with Nr2F1, Nr2F2, Sox9, Hoxa5, and 
Cyp26a1. RARγ, RXRα, and PolII association were characterized using publically available genome wide 
chromatin immunoprecipitation assays coupled with next generation DNA sequencing datasets (ChIP-seq). (A) 
Nr2F1, (B) Nr2F2, (C) Sox9, (D) Hoxa5, and (E) Cyp26a1 genomic loci in mouse F9 stem cells. ChIP-seq for 
untreated (0 h RA) and RA treated F9 cells (6 h and 48 h RA) are shown for RARγ (purple), RXRα (green), and 
RNA polII (blue). Each read is aligned to the corresponding genomic location, thereby visualizing specific 
chromatin association as density of reads. RefSeq intron and exon locations are specified in blue at the bottom 
of each alignment. Chromosome coordinates and scale bars are located at the top of each alignment. 
 
Figure S5. The Epigenetic signatures of Nr2F1, NR2F2, Hoxa5, and Cyp26a1. Histone modifications and 
PRC component association were characterized using publically available genome wide chromatin 
immunoprecipitation assays coupled with next generation DNA sequencing datasets (ChIP-seq). (A) Nr2F1, 
(B) Nr2F2, (C) Hoxa5 and (D) Cyp26a1 genes in mouse embryonic stem cells. Accession numbers for 
datasets used were for ChIPseq: F9 RARγ, F9 RXRα, F9 Pol II (GSE30538); ES H3K4me3, ES H3K27me3, 
ES RNA pol II (GSE12241); ES H3K4me1, ES H3K4me2 (GSE11172); PRC proteins, ES Suz12, ES EZH2, 
ES Ring1B (GSE13084); ES H3K27ac (GSE24165); Jarid2 (GSE465889). RNAseq: mRNA expression 
analysis of RA differentiated mouse ES cells (GSM566812). DNA methylation and hydroxymethylation state 
(GSE28682). 
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Table S1: Gene Expression Primers 
 
Forward Sense primer (5Õ-3Õ) Reverse Antisense primer (5Õ-3Õ) Product (bp) 
Induced by RA    cDNA gDNA 
mBMP2(+)A CTTAGACGGACTGCGGTCTCCTA mBMP2(-)B ACGTCTTCCGAAGGCCGGGACA 171 1238 
mCyp26a1(+)A GAAACATTGCAGATGGTGCTTCAG mCyp26a1(-)B CGGCTGAAGGCCTGCATAATCAC 272 728 
mCyp26b1(+)A TGGACTGTGTCATCAAGGAGGT mCyp26b1(-)B GTCGTGAGTGTCTCGGATGCTA 143 492 
mHoxa1(+)E TAACTCCTTATCCCCTCTCCAC mHoxa1(-)D ACCCACGTAGCCGTACTCTCCA 151 628 
mHoxa5(+)C CCCCTGGATGCGCAAGCTGCACATT mHoxa5(-)F TTCTCCAGCTCCAGGGTCTGGTAGCGA 105 1062 
mMeis1(+)A CATGATAGACCAGTCCAACC mMeis1(-)D GGCTACATACTCCCCTGGCATACT 243 3827 
mNR2F1(+)K AGCCATCGTGCTATTCACG mNR2F1(-)L TTCTCACCAGACACGAGGTC 570 5718 
mNR2F1(+)G CTGTCCCATCGACCAGCACCACCG mNR2F1(-)H GACAGGTAGCAGTGGCCATTGAGAG 177 2607 
mNR2F2(+)C GAAGATGCAAGCGGTTTGGGAC mNR2F2(-)D GGCAAACTGCCCGTGGGT 100 7908 
mSox9(+)C AGTACCCGCATCTGCACAAC mSox9(-)D TACTTGTAATCGGGGTGGTCT 145 938 
      
Controls      
mSuz12(+)A CGGCCACAAGAAATGGAAGTAGATA mSuz12(-)B TGCTGCATTTCTCGGAGCTT 335 2753 
m36B4(+)A AGAACAACCCAGCTCTGGAGAAA m36B4(-)B ACACCCTCCAGAAAGCGAGAGT 448 629 
      
Genotyping      
mRARαE34(+) TGGCTCAAACCACTCCATCGAGA mRARαE6(-) CCTGGTGCGCTTTGCGAACC 425 n/a 
mRARβE3a(+) GCAGCACCGGCATACTGCTC mRARβE4(-) CACTGACGCCATAGTGGTA 155 26450 
mRARγ2A(+) tttcaattgCCatgTACGACTGCATGGAATCGT mRARγE7(-) TTGCTGACCTTGGTGATGAGTT 551 6031 
 
 
 
Table S2: ChIP primers 
 
Forward Sense primer (5Õ-3Õ) Reverse Antisense primer (5Õ-3Õ) Product Position 
mNR2F1-p(+)M TGCCGCCTGTGCCATTTCTGAT mNR2F1-p(-)P CAGCGAGCGAGCTCCCTTCTCT 73 -70;+3 
mNR2F1-E(+)A GTCTTCTCGTTCGTTCGTTTGCTCTT mNR2F1-E(-)B CCTCATATTGTTGTGGGGCGGCT 277 -850;-773 
mHoxa5-p(+)G GCCATAATGGGCTGTAACCTCA mHoxa5-p(-)H ACCCGTTGCCGCCGTTCAGT 120 -160;-140 
mHoxa5-R(+)A CCTGAAGCTCAGTGCTGTGTATCT mHoxa5-R(-)B CTGTCTGGGCAGATGACTAAGAG 112 +7487;+7599 
      
 
 
 
